Sightsavers Logo
Research centre
  • Home
  • About us
  • Research approach
  • Research studies and publications
  • Evidence gap maps
Join in:
  • Join in: Facebook
  • Join in: Twitter
  • Join in: Instagram
  • Join in: LinkedIn
  • Join in: YouTube
  • Global
  • Close search bar
    Donate
    • Home
    • About us
    • Research approach
    • Research studies and publications
    • Evidence gap maps

    Screening for primary open angle glaucoma in the primary care setting: an update for the US Preventive Services Task Force

    Methodological quality of the review: Low confidence

    Author: Fleming C, Whitlock EP, Beil T, Smit B and Harris RP

    Geographical coverage: USA, however a trial from Sweden was included

    Sector: Glaucoma

    Sub-sector: Primary open angle glaucoma

    Equity focus: None specified

    Review type: Effectiveness review

    Quantitative synthesis method: Narrative

    Qualitative synthesis method: Not applicable

    Background: Primary open angle glaucoma (POAG) is one of the leading causes of blindness. For many years, glaucoma treatment with medications or surgery to lower intra-ocular pressure (IOP) had been the standard of care. There is no definitive evidence to support the benefit of treating persons with early glaucoma, and minimal visual impairment was not available.

    Objectives: To assess the effectiveness of screening for and treatment of early POAG in asymptomatic persons.

    Main findings: Two randomised controlled trials (RCTs) compared the efficacy of treatment to lower IOP with no treatment for persons who have early POAG. In a Swedish trial, treatment reduced progression at five years from 62% without treatment to 45% with treatment (absolute risk reduction [ARR] 17%, number needed to treat 5.8, P = .007).

    In a US trial of patients with early POAG and normal IOP, progression at five years was observed in 39% of those without treatment and 33% of those with treatment (P = .21). The principal side effect of treatment is loss of visual acuity as a result of increased risk of cataract formation. Authors conclude that the benefit of delaying progression of visual field loss on vision-related function in patients with early POAG is unclear.

    Methodology: Studies for glaucoma screening and treatment were identified from MEDLINE, the Cochrane Library and glaucoma experts. Relevant studies were appraised and data were extracted by two reviewers according to US Preventive Services Task Force criteria.

    Applicability/external validity: No methods were used either to assess the applicability/external validity of the results or to discuss how generalizable the results are.

    Geographic focus: This review focused on the USA. However, a relevant study from Sweden was included.

     

    Summary of quality assessment: The inclusion criteria were not stated, although a fairly comprehensive literature search was carried out using standard databases. It is not clear from the methodology of this review whether language bias was avoided or not, also we are not sure whether screening and abstracting data from relevant studies were done independently. There is no list of excluded studies. Therefore, there is low confidence in the conclusions about the effects of this study.

    Publication source: Fleming C, Whitlock EP, Beil T, Smit B and Harris RP. Screening for primary open angle glaucoma in the primary care setting: an update for the US Preventive Services Task Force. Ann Fam Med. 2005 Mar; 3(2): 167–170. Source
    Sightsavers Logo
    Research centre
    • Join in:
    • Join in: Facebook
    • Join in: X
    • Join in: Instagram
    • Join in: LinkedIn
    • Join in: YouTube

    Protecting sight, fighting disease and promoting equality for all

  • Accessibility
  • Sightsavers homepage
  • Our policies
  • Media centre
  • Contact us
  • Jobs
  • Cookies and privacy Terms and conditions Modern slavery statement Safeguarding

    © 2025 by Sightsavers, Inc., Business Address for all correspondence: One Boston Place, Suite 2600, Boston, MA 02108.

    Our website uses cookies

    To make sure you have a great experience on our site, we’d like your consent to use cookies. These will collect anonymous statistics to personalise your experience.

    Manage preferences

    You have the option to enable non-essential cookies, which will help us enhance your experience and improve our website.

    Essential cookiesAlways on

    These enable our site to work correctly, for example by storing page settings. You can disable these by changing your browser settings, but some parts of our website will not work as expected.

    Analytics cookies

    To improve our website, we’d like to collect anonymous data about how you use the site, such as which pages you read, the device you’re using, and whether your visit includes a donation. This is completely anonymous, and is never used to profile individual visitors.

    Advertising cookies

    To raise awareness about our work, we’d like to show you Sightsavers adverts as you browse the web. By accepting these cookies, our advertising partners may use anonymous information to show you our adverts on other websites you visit. If you do not enable advertising cookies, you will still see adverts on other websites, but they may be less relevant to you. For info, see the Google Ads privacy policy.